Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Sells $34,601.64 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 4,727 shares of Sera Prognostics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $34,601.64. Following the completion of the transaction, the general counsel now directly owns 135,528 shares in the company, valued at $992,064.96. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Sera Prognostics Stock Down 3.7 %

NASDAQ SERA opened at $6.97 on Thursday. Sera Prognostics, Inc. has a 52-week low of $1.65 and a 52-week high of $12.35. The stock has a market capitalization of $232.59 million, a P/E ratio of -7.04 and a beta of 1.04. The firm has a 50-day moving average price of $7.40 and a 200 day moving average price of $7.65.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same period in the prior year, the company posted ($0.23) EPS. On average, equities research analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors have recently bought and sold shares of SERA. MetLife Investment Management LLC grew its stake in Sera Prognostics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock worth $135,000 after buying an additional 9,722 shares during the period. Quest Partners LLC lifted its stake in shares of Sera Prognostics by 533.5% in the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after acquiring an additional 5,415 shares in the last quarter. Prime Capital Investment Advisors LLC purchased a new position in Sera Prognostics in the third quarter valued at about $104,000. SG Americas Securities LLC purchased a new stake in Sera Prognostics during the 3rd quarter worth approximately $78,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Sera Prognostics during the second quarter worth approximately $68,000. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.